CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.

NCT Number	NCT06892951
Lead Sponsor	University Hospital, Tours Collaborators: University Hospital, Angers, Centre Hospitalier Universitaire de Besancon, University Hospital, Bordeaux, University Hospital, Brest, Centre Hospitalier Universitaire Dijon, University Hospital, Grenoble, University Hospital, Lille, University Hospital, Limoges, Hospices Civils de Lyon, University Hospital, Montpellier, Nantes University Hospital, Centre Hospitalier Universitaire de Nice, Hospital Avicenne, Henri Mondor University Hospital, Hopital Foch, Hôpital Necker-Enfants Malades, Pitié-Salpêtrière Hospital, Poitiers University Hospital, Reims University hospital, Ohre Pharma, Aerogen, Wako Diagnostics, Cape Cod Incorporated, Institut National de la Santé Et de la Recherche Médicale, France, Tours university, Amiens University Hospital, Rennes University Hospital
Conditions	Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections
Enrollment	100 participants
Start Date	2025-06
Primary Completion	2026-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-03-25